| Literature DB >> 24917868 |
Miri Michaeli1, Hilla Tabibian-Keissar2, Ginette Schiby3, Gitit Shahaf1, Yishai Pickman1, Lena Hazanov1, Kinneret Rosenblatt3, Deborah K Dunn-Walters4, Iris Barshack5, Ramit Mehr1.
Abstract
Chronic gastritis is characterized by gastric mucosal inflammation due to autoimmune responses or infection, frequently with Helicobacter pylori. Gastritis with H. pylori background can cause gastric mucosa-associated lymphoid tissue lymphoma (MALT-L), which sometimes further transforms into diffuse large B-cell lymphoma (DLBCL). However, gastric DLBCL can also be initiated de novo. The mechanisms underlying transformation into DLBCL are not completely understood. We analyzed immunoglobulin repertoires and clonal trees to investigate whether and how immunoglobulin gene repertoires, clonal diversification, and selection in gastritis, gastric MALT-L, and DLBCL differ from each other and from normal responses. The two gastritis types (positive or negative for H. pylori) had similarly diverse repertoires. MALT-L dominant clones (defined as the largest clones in each sample) presented higher diversification and longer mutational histories compared with all other conditions. DLBCL dominant clones displayed lower clonal diversification, suggesting the transforming events are triggered by similar responses in different patients. These results are surprising, as we expected to find similarities between the dominant clones of gastritis and MALT-L and between those of MALT-L and DLBCL.Entities:
Keywords: B-cells; DLBCL; H. pylori; Ig gene; MALT lymphoma; gastritis; repertoire; somatic hypermutation
Year: 2014 PMID: 24917868 PMCID: PMC4042156 DOI: 10.3389/fimmu.2014.00264
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Graphic presentation of alpha, beta, and gamma diversity indices of order 1 and 2. Diversity measures were calculated, as described in the Section “Materials and Methods,” based on the Shannon entropy and the Simpson concentration diversity indices. The alpha diversity measure represents the average sample diversity in each condition/population. The gamma diversity measure represents the “global” repertoire diversity across all samples studied in each condition/population. The beta diversity measure represents the diversity component resulting from the variability between samples. In our Ig gene repertoire studies, the abundance data (numbers of unique sequences) of antibody clones in each sample was used to estimate the mean, standard error, and 95% confidence intervals (CI) of the total number of unique sequences in clones within each sample. The CI allows us to compare between diversity indices of different conditions. The error bars show the standard errors.
Figure 2Average percentages of clones in each VH–JH combination, in (A) GHP, (B) GNHP, and (C) CLN samples.
The average similarity between each pair of conditions.
| CLN | GNHP | GHP | |
|---|---|---|---|
| CLN | 0.211 | 0.295 | 0.343 |
| GNHP | 0.408 | 0.543 | |
| GHP | 0.478 |
Similarity measures were calculated between all clones in all samples in the compared conditions. In lymphomas, only the dominant clone(s) are relevant, as the rest of the clones in each sample represent other B-cells present in the tissue, which are not related to the malignancy. Thus, MALT-L and DLBCL are not included in the calculation of similarity measures because the dominant clones in these conditions cannot be compared to the full repertoire samples from other conditions.
A summary of frequent combinations and genes in conditions from our study and from other studies.
| Gene or combination | Common in our study in | Appeared in the literature in relation to |
|---|---|---|
| VH1-2 | MALT-L | Self-reactive antibodies, Bahler et al. ( |
| Chronic lymphocytic leukemia (B-CLL), primary central nervous system lymphomas, and splenic marginal zone lymphomas, Walsh and Rosenquist ( | ||
| VH1-3 | GNHP, GHP | B-CLL, Fais et al. ( |
| VH1-18 | GNHP, GHP, DLBCL | B-CLL, Fais et al. ( |
| Autoreactive gene, Yamashita et al. ( | ||
| BM-DLBCL, gastric MALT-Ls, Bende et al. ( | ||
| VH1-8 | DLBCL | B-CLL, Pimentel et al. ( |
| VH1-69 | MALT-L | Rheumatoid factor, Bende et al. ( |
| Gastric MALT-Ls, Bende et al. ( | ||
| B-CLL, Fais et al. ( | ||
| VH2-26/JH5 | MALT-L | FL, Bayerl et al. ( |
| VH2-26 | MALT-L | B-CLL, Pimentel et al. ( |
| Hairy cell leukemia, Hashimoto et al. ( | ||
| VH3-7 | MALT-L Dominant, DLBCL | Rheumatoid factor, Bende et al. ( |
| Rheumatoid arthritis, Nakamura-Kikuoka et al. ( | ||
| Sjögren syndrome, Bahler and Swerdlow ( | ||
| B-CLL, Fais et al. ( | ||
| BM-DLBCL, Yamashita et al. ( | ||
| Gastric MALT-Ls, Bende et al. ( | ||
| VH3-23 | DLBCL | IgM+ B-cells, Brezinschek et al. ( |
| Naïve B-cells, Wu et al. ( | ||
| Anti-DNA auto-antibodies, Matsuda et al. ( | ||
| Hepatitis C virus-related mixed cryoglobulinemia, Perotti et al. ( | ||
| Unmutated VH3-23 in transformation from B-CLL into DLBCL, Mao et al. ( | ||
| Gastric MALT lymphomagenesis, Sakuma et al. ( | ||
| BM-DLBCL, Yamashita et al. ( | ||
| B-CLL, Pimentel et al. ( | ||
| VH3-30 | DLBCL | Rheumatoid factor, Bende et al. ( |
| Gastric MALT lymphomagenesis, Sakuma et al. ( | ||
| B-CLL, Pimentel et al. ( | ||
| VH3-30/JH4 | DLBCL | FL, Bayerl et al. ( |
| VH5-51 and VH6-1 | CLN, GNHP, GHP, and DLBCL | Auto-antigens, Matsuda et al. ( |
| Dominant |
The dominant segments are marked with “Dominant” indication. The dominant segments/combinations are those that appeared in the largest clone in each sample.
.
VDJ combinations that were over-expressed in each condition.
| Condition | Combination | Mean difference | |
|---|---|---|---|
| GNHP | V2D1J6 | 0.009 | 3.57 |
| V3D5J4 | 0.002 | 4.38 | |
| V3D0J5 | 0.001 | 7.84 | |
| V6D6J6 | 0.035 | 3.84 | |
| V6D3J6 | 0.042 | 3.60 | |
| GHP | V3D0J5 | 0.035 | 10.44 |
| V5D3J2 | 0.015 | 3.26 | |
| DLBCL | V1D1J6 | 0.011 | 1.30 |
| Dominant | |||
| V1D4J3 | 0.000 | 4.94 | |
| V4D6J4 | 0.046 | 2.70 | |
| V5D1J4 | 0.001 | 1.80 | |
| Dominant | |||
| V5D7J4 | 0.036 | 2.20 | |
| V6D6J6 | 0.000 | 3.47 | |
| V6D3J6 | 0.003 | 3.50 |
.
.
.
.
Figure 3Average percentages of clones in each VH–JH combination, in (A) DLBCL and (B) MALT-L samples.
Figure 4Lineage tree analysis – comparison between dominant clones from the three MALT-L samples (24 trees) and the five DLBCL samples (47 trees). There was more than one tree per sample, as we included all clones with the same VH and JH genes (but different alleles) in the dominant clone in each sample, because they might be related to the dominant clone and falsely attributed to other alleles. Significant differences were found in trunk length (T) and minimal path length (PLmin). An asterisk (*) represents p-value <0.01; two asterisks (**) represents p-value <0.005.
Number of unique sequences.
| CLN | GNHP | GHP | MALT-L | DLBCL | Total | |
|---|---|---|---|---|---|---|
| Number of patients (samples) | 19 | 7 | 3 | 3 | 5 | 37 |
| Number of unique sequences | 23,308 | 4,676 | 3,373 | 3,851 | 4,389 | 39,597 |
| Range of sequences | 384–3,353 | 75–1,105 | 513–1,406 | 838–1,854 | 267–1,601 | |
| Dominant clone sizes | 360 (249) | 162 (49) | ||||
| 461 (399) | 325 (257) | |||||
| 408 (321) | 58 (42) | |||||
| 78 (47) | ||||||
| 418 (193) |
.
.
.
.
Figure 5Illustration of the calculation of repertoire diversity. First, the diversity indices (Shannon entropy, Simpson concentration index, etc.) are calculated for the pool of samples in each condition and also for each sample separately (samples are denoted by X1, …, Xn. Diversity indices are denoted by D (sample) or D (pool)). Next, the distribution measures (α, β, γ) are calculated for each condition using the samples. γ is the pool diversity, α is the mean sample diversity, and β for each sample is γ divided by D (sample). Finally, the CIs of the distribution measures are compared between the populations/conditions.